WO2020071931A1 - Method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing synovial fluid - Google Patents

Method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing synovial fluid

Info

Publication number
WO2020071931A1
WO2020071931A1 PCT/PL2019/000082 PL2019000082W WO2020071931A1 WO 2020071931 A1 WO2020071931 A1 WO 2020071931A1 PL 2019000082 W PL2019000082 W PL 2019000082W WO 2020071931 A1 WO2020071931 A1 WO 2020071931A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
supplementing
synovial fluid
aqueous
viscoelastic gel
Prior art date
Application number
PCT/PL2019/000082
Other languages
French (fr)
Other versions
WO2020071931A8 (en
Inventor
Błażej DOLNIAK
Barbara ZAKRZEWSKA
Original Assignee
Dolniak Blazej
Zakrzewska Barbara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dolniak Blazej, Zakrzewska Barbara filed Critical Dolniak Blazej
Publication of WO2020071931A1 publication Critical patent/WO2020071931A1/en
Publication of WO2020071931A8 publication Critical patent/WO2020071931A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/10—Materials for lubricating medical devices

Definitions

  • the subject of the invention is a method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing the synovial fluid, which is widely used in veterinary medicine for alleviating the symptoms of joint dysfunction by increasing the slip on the surface of connective tissue.
  • the implantable hydrogel of acrylamide copolymer for therapeutic purposes known from Polish patent application No. P.327454 is a copolymer of N-substituted methacrylamide or acrylamide, a crosslinker and a material selected from the group consisting of complex sugar, sugar derivative, tissue adhesive peptide and polymer conjugated with anti-lipid antibodies, wherein the polymer hydrogel is heterogeneous, it is elastically deformable and has an equilibrium water content of at least about 80% as well as a method for its production. It can be used for tissue regeneration or organ repair, for example in the developing or adult nervous system.
  • a multifunctional biocompatible hydrogel and method of its preparation are known from European Patent EP1438976.
  • the hydrogel contains 1.3-15% weight acrylamide, 0.004 - 0.975% mass crosslinkers N, N'-methylene-bis-acrylamide, N, N'- ethylene-bis-acrylamide in the amount of 0.004 - 5.1% mass , poviargolum in an amount of 0.002 - 0.45% mass and water - up to 100% mass.
  • the hydrogel is produced by copolymerization of acrylamide with cross-linking agents in an aqueous environment in the presence of a polymerization initiator, the incubation of the reaction mixture being carried in two stages; the first of which is carried out at a temperature of 20-90°C for 2-24 hours, and the second - at l07-l30°C during a time equal to or less than 2 hours.
  • the substantial of the method according to the invention is that the aqueous polymer solution with an average molecular weight above 1500 Da and a concentration of 0.1% to 40% by weight, preferably polyvinylpyrrolidone and/or polyvinyl alcohol and/or hyaluronic acid, is mixed with aqueous gold colloid solution of 0.001% to 0.04% by weight and/or aqueous silver colloid solution of 0.001% to 0.04% by weight, with one part by volume of aqueous polymer solution being mixed for at least 15 minutes with one to four parts by volume of aqueous gold and/or silver colloid solution.
  • aqueous polymer solution with an average molecular weight above 1500 Da and a concentration of 0.1% to 40% by weight preferably polyvinylpyrrolidone and/or polyvinyl alcohol and/or hyaluronic acid
  • the viscoelastic gel supplementing the synovial fluid according to the invention restores the proper viscosity level of the synovial fluid, relieves the symptoms of joint dysfunction, increases the slip on the connective tissue surface, reduces further damage of the joint cartilage, relieves pain by reducing the friction between joint structures in the joint, absorbs the forces affecting joint structures in the joint, improves joint function.
  • it contains silver and/or gold nanoparticles that are used as bactericidal material, as a carrier for drugs as well as for the formation of gels and ointments with bactericidal properties.
  • the method of obtaining a viscoelastic gel supplementing the synovial fluid is based on preparation of 500 ml of an aqueous solution containing 24% by weight of polyvinylpyrrolidone and 0.1% by weight of hyaluronic acid, which is then mixed with 250 ml of 0.04% by weight of aqueous gold colloidal solution and with 250 ml of 0.001% by weight of silver aqueous colloidal solution. The whole solution is mixed for a minimum 30 min.
  • the viscous-elastic gel supplementing synovial fluid prepared in this way contains: 12% by weight of polyvinylpyrrolidone, 0.05% by weight of hyaluronic acid, 0.01% by weight of colloidal gold and 0.00025 % by weight of colloidal silver.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid is based on the fact that to 500 ml of an aqueous solution containing 12% by weight of polyvinyl alcohol and 10% by weight of polyvinylpyrrolidone 250 ml 0.01% by weight of gold colloidal solution and 250 ml 0.04% by weight of gold colloidal silver 0.04 wt are added. The whole solution is mixed for 2 hours.
  • the viscoelastic gel supplementing the synovial fluid prepared in this way contains: 6% by weight of polyvinyl alcohol, 5% by weight of polyvinylpyrrolidone, 0.0025% by weight of colloidal gold and 0.01% by weight of colloidal silver dissolved in water.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of 500 ml of an aqueous solution containing 12% by weight of polyvinyl alcohol, 0.6% by weight of hyaluronic acid, 250 ml of 0.02% by weight gold colloidal solution and 250 ml of 0.02% by weight colloidal silver solution. The whole solution is stirred for 1 hour.
  • the viscoelastic gel supplementing the synovial fluid prepared in this way contains: 6% by weight of polyvinyl alcohol, 0.3% by weight of hyaluronic acid, 0.005% by weight of colloidal gold and 0.005% by weight of colloidal silver dissolved in water.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 12% by weight of polyvinyl alcohol, 12% by weight of polyvinylpyrrolidone and 0.2% by weight of hyaluronic acid and 250 ml of 0.001% by weight of gold colloidal gold solution and 250 ml 0.01% by weight of gold colloidal silver which are added to it. The whole solution is stirred for 30 min.
  • the viscoelastic gel supplementing the synovial fluid prepared in this way contains: 6% by weight of polyvinyl alcohol, 6% by weight of polyvinylpyrrolidone, 0.1% bt weight of hyaluronic acid, 0.00025% by weight of colloidal gold and 0.0025% by weight of colloidal silver dissolved in water.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 24% by weight of polyvinyl alcohol and 500 ml 0.02% by weight of gold colloidal gold solution which is added to it. The whole solution is stirred for 15 min.
  • the viscous-elastic gel supplementing the synovial fluid prepared in this way contains: 12% by weight of polyvinyl alcohol and 0.01% by weight of colloidal gold dissolved in water.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 24% by weight of polyvinylpyrrolidone and 500 ml of a 0.001% by weight of aqueous colloidal silver solution which is added to it. The whole solution is mixed for 15 minutes.
  • the viscous- elastic gel supplementing the synovial fluid prepared in this way contains: 12% by weight of polyvinylpyrrolidone and 0.0005% by weight of colloidal silver dissolved in water.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 2% by weight of hyaluronic acid and 500 ml of 0.04% by weight of gold colloidal gold solution which is added to it. The whole solution is stirred for 30 min.
  • the viscous-elastic gel supplementing the synovial fluid prepared in this way contains: 1% by weight of hyaluronic acid and 0.02% by weight of colloidal gold dissolved in water.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 40% by weight of polyvinyl alcohol, 200 ml of 0.04% by weight of gold colloidal gold solution and 50 ml 0.024% by weight of an aqueous colloidal silver solution is added to it. The whole solution is stirred for 1 hour.
  • the viscous-elastic gel supplementing the synovial fluid prepared in this way contains: 26.6% by weight of polyvinyl alcohol, 0.0064% by weight of colloidal gold and 0.0016% by weight of colloidal silver dissolved in water.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 250 ml of an aqueous solution containing 24% by weight of polyvinyl alcohol and 500 ml 0.012% by weight of gold colloidal gold solution. The whole solution is stirred for 1 hour.
  • the viscoelastic gel supplementing the synovial fluid prepared in this way contains: 8% by weight of polyvinyl alcohol and 0.008% by weight of colloidal gold dissolved in water.
  • the method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 250 ml of an aqueous solution containing 4% by weight of hyaluronic acid and 750 ml of 0.03% by weight of gold colloidal solution. 250 ml 0.004% of aqueous colloidal silver solution is added to it. The whole solution is stirred for 2 hours.
  • the viscoelastic gel supplementing the synovial fluid prepared in this way contains: 0.8% by weight of hyaluronic acid, 0.018% by weight of colloidal gold and 0.0008% by weight of colloidal silver dissolved in water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The subject of the invention is a method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing synovial fluid, which is widely used in veterinary medicine for alleviating the symptoms of joint dysfunction by increasing the slip on the surface of connective tissue. The essence of the method is that the aqueous polymer solution with an average molecular weight above 1500 Da and a concentration of 0.1% to 40% by weight, preferably polyvinylpyrrolidone and/or polyvinyl alcohol and/or hyaluronic acid, is mixed with aqueous gold colloid solution of 0.001% to 0.04% by weight and/or aqueous silver colloid solution of 0.001% to 0.04% by weight, with one part by volume of aqueous polymer solution being mixed for at least 15 minutes with one to four parts by volume of aqueous gold and/or silver colloid solution. The viscous-elastic gel contains water in which the polymer with an average molecular weight above 1500 Da is dissolved in an amount of 0.08% by weight to 26.6% by weight, preferably polyvinylpyrrolidone and/or polyvinyl alcohol and/or hyaluronic acid and colloidal gold in an amount of 0.0025% by weight to 0.01% by weight and/or colloidal silver in an amount of 0.00025% by weight to 0.01% by weight.

Description

Method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing synovial fluid.
The subject of the invention is a method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing the synovial fluid, which is widely used in veterinary medicine for alleviating the symptoms of joint dysfunction by increasing the slip on the surface of connective tissue.
The implantable hydrogel of acrylamide copolymer for therapeutic purposes known from Polish patent application No. P.327454, is a copolymer of N-substituted methacrylamide or acrylamide, a crosslinker and a material selected from the group consisting of complex sugar, sugar derivative, tissue adhesive peptide and polymer conjugated with anti-lipid antibodies, wherein the polymer hydrogel is heterogeneous, it is elastically deformable and has an equilibrium water content of at least about 80% as well as a method for its production. It can be used for tissue regeneration or organ repair, for example in the developing or adult nervous system.
A multifunctional biocompatible hydrogel and method of its preparation are known from European Patent EP1438976. The hydrogel contains 1.3-15% weight acrylamide, 0.004 - 0.975% mass crosslinkers N, N'-methylene-bis-acrylamide, N, N'- ethylene-bis-acrylamide in the amount of 0.004 - 5.1% mass , poviargolum in an amount of 0.002 - 0.45% mass and water - up to 100% mass. The hydrogel is produced by copolymerization of acrylamide with cross-linking agents in an aqueous environment in the presence of a polymerization initiator, the incubation of the reaction mixture being carried in two stages; the first of which is carried out at a temperature of 20-90°C for 2-24 hours, and the second - at l07-l30°C during a time equal to or less than 2 hours.
The substantial of the method according to the invention is that the aqueous polymer solution with an average molecular weight above 1500 Da and a concentration of 0.1% to 40% by weight, preferably polyvinylpyrrolidone and/or polyvinyl alcohol and/or hyaluronic acid, is mixed with aqueous gold colloid solution of 0.001% to 0.04% by weight and/or aqueous silver colloid solution of 0.001% to 0.04% by weight, with one part by volume of aqueous polymer solution being mixed for at least 15 minutes with one to four parts by volume of aqueous gold and/or silver colloid solution.
The viscoelastic gel supplementing the synovial fluid according to the invention restores the proper viscosity level of the synovial fluid, relieves the symptoms of joint dysfunction, increases the slip on the connective tissue surface, reduces further damage of the joint cartilage, relieves pain by reducing the friction between joint structures in the joint, absorbs the forces affecting joint structures in the joint, improves joint function. In addition, it contains silver and/or gold nanoparticles that are used as bactericidal material, as a carrier for drugs as well as for the formation of gels and ointments with bactericidal properties.
The objects of the inventions are explained in the following examples of implementation.
Example 1
The method of obtaining a viscoelastic gel supplementing the synovial fluid is based on preparation of 500 ml of an aqueous solution containing 24% by weight of polyvinylpyrrolidone and 0.1% by weight of hyaluronic acid, which is then mixed with 250 ml of 0.04% by weight of aqueous gold colloidal solution and with 250 ml of 0.001% by weight of silver aqueous colloidal solution. The whole solution is mixed for a minimum 30 min. The viscous-elastic gel supplementing synovial fluid prepared in this way contains: 12% by weight of polyvinylpyrrolidone, 0.05% by weight of hyaluronic acid, 0.01% by weight of colloidal gold and 0.00025 % by weight of colloidal silver.
Example 2
The method of synthesis of a viscoelastic gel supplementing the synovial fluid is based on the fact that to 500 ml of an aqueous solution containing 12% by weight of polyvinyl alcohol and 10% by weight of polyvinylpyrrolidone 250 ml 0.01% by weight of gold colloidal solution and 250 ml 0.04% by weight of gold colloidal silver 0.04 wt are added. The whole solution is mixed for 2 hours. The viscoelastic gel supplementing the synovial fluid prepared in this way contains: 6% by weight of polyvinyl alcohol, 5% by weight of polyvinylpyrrolidone, 0.0025% by weight of colloidal gold and 0.01% by weight of colloidal silver dissolved in water. Example 3
The method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of 500 ml of an aqueous solution containing 12% by weight of polyvinyl alcohol, 0.6% by weight of hyaluronic acid, 250 ml of 0.02% by weight gold colloidal solution and 250 ml of 0.02% by weight colloidal silver solution. The whole solution is stirred for 1 hour. The viscoelastic gel supplementing the synovial fluid prepared in this way contains: 6% by weight of polyvinyl alcohol, 0.3% by weight of hyaluronic acid, 0.005% by weight of colloidal gold and 0.005% by weight of colloidal silver dissolved in water.
Example 4
The method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 12% by weight of polyvinyl alcohol, 12% by weight of polyvinylpyrrolidone and 0.2% by weight of hyaluronic acid and 250 ml of 0.001% by weight of gold colloidal gold solution and 250 ml 0.01% by weight of gold colloidal silver which are added to it. The whole solution is stirred for 30 min. The viscoelastic gel supplementing the synovial fluid prepared in this way contains: 6% by weight of polyvinyl alcohol, 6% by weight of polyvinylpyrrolidone, 0.1% bt weight of hyaluronic acid, 0.00025% by weight of colloidal gold and 0.0025% by weight of colloidal silver dissolved in water.
Example 5
The method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 24% by weight of polyvinyl alcohol and 500 ml 0.02% by weight of gold colloidal gold solution which is added to it. The whole solution is stirred for 15 min. The viscous-elastic gel supplementing the synovial fluid prepared in this way contains: 12% by weight of polyvinyl alcohol and 0.01% by weight of colloidal gold dissolved in water.
Example 6
The method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 24% by weight of polyvinylpyrrolidone and 500 ml of a 0.001% by weight of aqueous colloidal silver solution which is added to it. The whole solution is mixed for 15 minutes. The viscous- elastic gel supplementing the synovial fluid prepared in this way contains: 12% by weight of polyvinylpyrrolidone and 0.0005% by weight of colloidal silver dissolved in water.
Example 7
The method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 2% by weight of hyaluronic acid and 500 ml of 0.04% by weight of gold colloidal gold solution which is added to it. The whole solution is stirred for 30 min. The viscous-elastic gel supplementing the synovial fluid prepared in this way contains: 1% by weight of hyaluronic acid and 0.02% by weight of colloidal gold dissolved in water.
Example 8
The method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 500 ml of an aqueous solution containing 40% by weight of polyvinyl alcohol, 200 ml of 0.04% by weight of gold colloidal gold solution and 50 ml 0.024% by weight of an aqueous colloidal silver solution is added to it. The whole solution is stirred for 1 hour. The viscous-elastic gel supplementing the synovial fluid prepared in this way contains: 26.6% by weight of polyvinyl alcohol, 0.0064% by weight of colloidal gold and 0.0016% by weight of colloidal silver dissolved in water.
Example 9
The method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 250 ml of an aqueous solution containing 24% by weight of polyvinyl alcohol and 500 ml 0.012% by weight of gold colloidal gold solution. The whole solution is stirred for 1 hour. The viscoelastic gel supplementing the synovial fluid prepared in this way contains: 8% by weight of polyvinyl alcohol and 0.008% by weight of colloidal gold dissolved in water.
Example 10
The method of synthesis of a viscoelastic gel supplementing the synovial fluid consists of preparation of 250 ml of an aqueous solution containing 4% by weight of hyaluronic acid and 750 ml of 0.03% by weight of gold colloidal solution. 250 ml 0.004% of aqueous colloidal silver solution is added to it. The whole solution is stirred for 2 hours. The viscoelastic gel supplementing the synovial fluid prepared in this way contains: 0.8% by weight of hyaluronic acid, 0.018% by weight of colloidal gold and 0.0008% by weight of colloidal silver dissolved in water.

Claims

Claims
1. Method for the production of a viscoelastic gel supplementing the synovial fluid is characterized in that the aqueous polymer solution with an average molecular weight above 1500 Da and a concentration of 0.1% to 40% by weight, preferably polyvinylpyrrolidone and/or polyvinyl alcohol and/or hyaluronic acid, is mixed with aqueous gold colloid solution of 0.001% to 0.04% by weight and / or aqueous silver colloid solution of 0.001% to 0.04% by weight, with one part by volume of aqueous polymer solution being mixed for at least 15 minutes with one to four parts by volume of aqueous gold and/or silver colloid solution.
2. The viscous-elastic gel supplementing the synovial fluid is characterized in that it contains water in which the polymer with an average molecular weight above 1500 Da is dissolved in an amount of 0.08% by weight to 26.6% by weight, preferably polyvinylpyrrolidone and/or polyvinyl alcohol and/or hyaluronic acid and colloidal gold in an amount of 0.0025% by weight to 0.01% by weight and/or colloidal silver in an amount of 0.00025% by weight to 0.01% by weight.
PCT/PL2019/000082 2018-10-01 2019-09-20 Method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing synovial fluid WO2020071931A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.427322 2018-10-01
PL427322A PL241064B1 (en) 2018-10-01 2018-10-01 Method of producing for producing a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing the synovial fluid
PLP,.427322 2018-10-01

Publications (2)

Publication Number Publication Date
WO2020071931A1 true WO2020071931A1 (en) 2020-04-09
WO2020071931A8 WO2020071931A8 (en) 2020-06-04

Family

ID=69005793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2019/000082 WO2020071931A1 (en) 2018-10-01 2019-09-20 Method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing synovial fluid

Country Status (2)

Country Link
PL (1) PL241064B1 (en)
WO (1) WO2020071931A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL327454A1 (en) 1996-10-16 1998-12-07 Organogel Canada Ltee Implantable hydrogel of an acrylamide polymer for therapeutic purposes
EP1438976A1 (en) 2001-09-28 2004-07-21 Biopharma Development Ltd Polyfunctional biocompatible hydrogel and method for the production thereof
WO2006112632A1 (en) * 2005-04-18 2006-10-26 Benjamin Won Park Urethral condoms and liquid femidoms
WO2013021249A1 (en) * 2011-08-10 2013-02-14 Glycores 2000 S.R.L. Degradation-resistant cross-linked, low-molecular-weight hyaluronate
WO2015048988A1 (en) * 2013-10-02 2015-04-09 Ao Technology Ag Thermosensitive hyaluronic acid conjugates and methods for the preparation thereof
EP3088011A1 (en) * 2013-12-26 2016-11-02 International Business Company "Newcross Ventures Ltd." Polyacrylamide hydrogel-based material for medical purposes and method for producing same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL327454A1 (en) 1996-10-16 1998-12-07 Organogel Canada Ltee Implantable hydrogel of an acrylamide polymer for therapeutic purposes
EP1438976A1 (en) 2001-09-28 2004-07-21 Biopharma Development Ltd Polyfunctional biocompatible hydrogel and method for the production thereof
WO2006112632A1 (en) * 2005-04-18 2006-10-26 Benjamin Won Park Urethral condoms and liquid femidoms
WO2013021249A1 (en) * 2011-08-10 2013-02-14 Glycores 2000 S.R.L. Degradation-resistant cross-linked, low-molecular-weight hyaluronate
WO2015048988A1 (en) * 2013-10-02 2015-04-09 Ao Technology Ag Thermosensitive hyaluronic acid conjugates and methods for the preparation thereof
EP3088011A1 (en) * 2013-12-26 2016-11-02 International Business Company "Newcross Ventures Ltd." Polyacrylamide hydrogel-based material for medical purposes and method for producing same

Also Published As

Publication number Publication date
PL427322A1 (en) 2020-04-06
WO2020071931A8 (en) 2020-06-04
PL241064B1 (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US11707526B2 (en) Polymer hydrogels for in vivo applications and methods for using and preparing same
Sun et al. Covalently crosslinked hyaluronic acid‐chitosan hydrogel containing dexamethasone as an injectable scaffold for soft tissue engineering
CA2550718A1 (en) Cohesive gels from cross-linked hyaluronan and/or hylan, their preparation and use
US11098168B2 (en) Method for preparing cross-linked hyaluronic acid gel and cross-linked hyaluronic acid gel prepared by the same
EP2817013A2 (en) Antimicrobial compositions, the preparation and use thereof
US20140220082A1 (en) Adhesive complex coacervates and methods of making and using thereof
CN110845743A (en) Quadruple hydrogen bond-based polyamino acid-based self-healing hydrogel and preparation method thereof
CN101519474A (en) Double-response water gel with high swelling property and synthetic method
CA2756792A1 (en) Implant filling material and method
US20150126619A1 (en) Ionic gel
KR20200020423A (en) dual-mode drug release hydrogel and method of fabricating the same
CN109851716A (en) A kind of water soluble chitosan and preparation method thereof with temperature sensitive properties
US10077324B2 (en) Polymers, preparation and use thereof
Fan et al. Highly stretchable, swelling-resistant, self-healed, and biocompatible dual-reinforced double polymer network hydrogels
WO2020071931A1 (en) Method for the production of a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing synovial fluid
CN110627976A (en) Tussah silk fibroin hydrogel and preparation method and application thereof
CZ2010687A3 (en) Process for preparing extremely substituted hyaluronic acid amides x
CN112641994A (en) Sports colloid dressing based on betaine derivative and alginate
KR102029926B1 (en) Hydrogel hemostatic material comprising pullulan and manufacturing method thereof
CN112480389B (en) Low-oxygen responsive injectable hydrogel and preparation method thereof
CN114230708A (en) Carbomer and preparation method thereof
Serafim et al. New hydrogels based on gelatin and acrylamide
CN114015074B (en) Carboxymethyl chitosan/polyacrylamide injectable self-healing hydrogel and preparation method and application thereof
CN113717385A (en) Glass polymer with shearing hardening characteristic
CN109280129B (en) Injectable hydrogel polymer based on salt response under physiological conditions and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19827851

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19827851

Country of ref document: EP

Kind code of ref document: A1